As “the premier global event in oncology,” the Annual ASCO Meeting is one of the most highly anticipated oncology conferences of the year and we are thrilled to be participating this year with a team onsite! The meeting is a fantastic forum to discuss and debate the current standards of cancer care and work together to determine how to improve upon ongoing issues and controversies. We are excited to announce that this year we will be sharing our ATRACTIB and LUPER trials.
Lurbinectin is a novel agent that inhibits the transcription of encoding genes which promotes tumor death and stabilizes the tumor microenvironment. It is currently FDA approved to treat metastatic small cell lung cancer patients who have progressed on platinum-based chemotherapy. With this in mind, our prospective, open-label, phase I/II LUPER trial is assessing the safety/tolerability and clinical response of lurbinectedin in combination with pembrolizumab as second-line therapy for patients with relapsed small-cell lung cancer (SCLC). Eligible patients must have histologically confirmed SCLC, have progressed on a previous chemotherapy-containing regimen, no previous immunotherapy treatment, ECOG performance status of 0-1, and measurable disease per RECIST 1.1. Of note, patients with treated, stable, and asymptomatic brain metastases are also eligible to participate in the trial. The maximum tolerated dose and recommended phase II dose of lurbinectedin in combination with pembrolizumab from the Phase 1 phase will be shared at the meeting.
We will also present our international, open-label, phase II ATRACTIB trial, which just completed recruitment this month! While there has been a substantial benefit from adding immune checkpoint inhibitors to chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC) with PD-L1-positive tumors, there are many patients that will still have a poor outcome. Therefore, the ATRACTIB trial is exploring the combination of atezolizumab, bevacizumab, and paclitaxel for patients with mTNBC, regardless of their PD-L1 status. At the meeting we will be sharing the data from the safety interim analysis which includes the first 20 patients who had completed a 3-month follow-up or reached the end of the study.
We are excited to have a team onsite this year at the conference and are looking forward to learning about the most up-to-date and practice changing research that will be presented at the meeting. Connect with us to set up you’re meeting or if you want to learn more about these studies!
Comments